The mission of the UCSF-Gladstone Center for AIDS Research (CFAR) is to promote multidisciplinary research at the intersection of the basic, clinical, and behavioral-epidemiological sciences with the goal of ending the global HIV epidemic. To fulfill its mission, CFAR collaborates with UCSF's AIDS Research Institute and the Center for AIDS Prevention Studies (CAPS), as well as the newly funded amfAR Institute for HIV Cure Research, to coordinate a multi-pronged program that aims to: 1) Provide administrative and scientific leadership through a proactive planning process that identifies the most important challenges emerging at the cutting edge of HIV research 2) Identify, mentor, and support a highly skilled, diverse, and thoughtful next generation of HIV investigators by providing a strong mentoring program unique to UCSF and through a California-funded Health Disparities Core linked to CFAR 3) Conduct a dynamic pilot grants program to accelerate discovery 4) Maintain an outstanding set of scientific cores to extend the reach of Center investigators' research 5) Ensure our programs support major NIH-funded HIV/AIDS research programs and OAR priorities 6) Confront domestic prevention and treatment disparities through effective local collaborations 7) Direct CFAR's research and capacity building programs to international sites where the epidemic is hitting the hardest 8) Engage the communities we serve through a set of novel alliances involving Project Inform, the Forum for Collaborative HIV Research, and UCSF's Science and Health Education Partnership 9) Forge effective inter-CFAR collaborations to nucleate research teams across different disciplines and sites to address all dimensions of these identified challenges CFAR brings value by creating and sustaining a true community of HIV/AIDS science. CFAR is proud of its accomplishments in the last four years including: the publication of 791 papers; the mentoring of 69 early career investigators; the award of $6.1 million to support 79 CFAR grants and supplements; the success of recent CFAR awardees in winning more than $106.7 million dollars in peer-reviewed, HIV-related funding; and our continuing engagement in the planning and organization of the East Africa Collaborative Scientific Symposium and Sub-Saharan Africa CFAR Conferences featuring the work of African scientists. However, much work remains to be done. CFAR looks forward to helping stimulate progress on multiple scientific fronts including increasing access to implementation science methods, driving progress in HIV eradication, increasing access to proven biomedical approaches to HIV prevention and addressing disparities in HIV care and treatment within resource-limited communities in the Bay Area and abroad.

Public Health Relevance

The mission of the UCSF-Gladstone Center for AIDS Research (CFAR) is to promote multidisciplinary research at the intersection of the basic, clinical, and behavioral-epidemiological sciences with the goal of ending the global HIV epidemic. To fulfill its mission, CFAR collaborates with UCSF's AIDS Research Institute and the Center for AIDS Prevention Studies (CAPS), as well as the newly funded amfAR Institute for HIV Cure Research, to coordinate a multi-pronged program that aims to: Provide administrative and scientific leadership through a proactive planning process that identifies the most important challenges emerging at the cutting edge of HIV research; Identify, mentor, and support a highly skilled, diverse, and thoughtful next generation of HIV investigators by providing a strong mentoring program unique to UCSF and through a California-funded Health Disparities Core linked to CFAR; Conduct a dynamic pilot grants program to accelerate discovery; Maintain an outstanding set of scientific cores to extend the reach of Center investigators' research; Ensure our programs support major NIH-funded HIV/AIDS research programs and OAR priorities; Confront domestic prevention and treatment disparities through effective local collaborations; Direct CFAR's research and capacity building programs to international sites where the epidemic is hitting the hardest Engage the communities we serve through a set of novel alliances involving Project Inform, the Forum for Collaborative HIV Research, and UCSF's Science and Health Education Partnership; and Forge effective inter-CFAR collaborations to nucleate research teams across different disciplines and sites to address all dimensions of these identified challenges. CFAR brings value by creating and sustaining a true community of HIV/AIDS science. CFAR is proud of its accomplishments in the last four years including: the publication of 791 papers; the mentoring of 69 early career investigators; the award of $6.1 million to support 79 CFAR grants and supplements; the success of recent CFAR awardees in winning more than $106.7 million dollars in peer- reviewed, HIV-related funding; and our continued engagement in East Africa. CFAR will to helping stimulate progress on multiple scientific fronts including increasing access to implementation science methods, driving progress in HIV eradication, increasing access to proven biomedical approaches to HIV prevention and addressing disparities in HIV care and treatment within resource-limited communities in the Bay Area and abroad.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-27
Application #
9502898
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
1997-03-01
Project End
2022-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
27
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Yukl, Steven A; Kaiser, Philipp; Kim, Peggy et al. (2018) HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10:
Roy, Monika; Holmes, Charles; Sikazwe, Izukanji et al. (2018) Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia. Clin Infect Dis 67:1269-1277
Kiniry, Brenna E; Hunt, Peter W; Hecht, Frederick M et al. (2018) Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. J Immunol 200:1876-1888
Jeng, Mark Y; Hull, Philip A; Fei, Mingjian et al. (2018) Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1. J Exp Med 215:51-62
Chitre, Avantika S; Kattah, Michael G; Rosli, Yenny Y et al. (2018) A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathog 14:e1006806
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Leonard, Brandon; Brand, Toni M; O'Keefe, Rachel A et al. (2018) BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res 78:4331-4343
Wang, Chia-Ching; Thanh, Cassandra; Gibson, Erica A et al. (2018) Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv 2:3479-3482
Castillo-Mancilla, Jose R; Morrow, Mary; Boum, Yap et al. (2018) Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr 77:507-513

Showing the most recent 10 out of 1541 publications